Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors

Published:2023-08 Issue:8 Volume:23 Page:610-615
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chiu Chia-Yu^ORCID,Ahmed Sairah,Thomas Sheeba K.,Wang Lan Sun,Mustafayev Khalis,Fayad Luis E.,Wierda William G.,Khawaja Fareed^ORCID,Torres Harrys A.^ORCID

Funder

National Cancer Institute

University of Texas MD Anderson Cancer Center

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference13 articles.

1. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy;Ni;Front Immunol,2022

2. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study;Xu;J Hematol Oncol,2020

3. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies;Mustafayev;Clin Microbiol Infect,2022

4. Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study;Innocenti;Haematologica,2022

5. Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review;Lu;Lancet Haematol,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments;World Journal of Gastroenterology;2024-07-07

2. Bruton's tyrosine kinase inhibition for the treatment of allergic disorders;Annals of Allergy, Asthma & Immunology;2024-07

3. Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors;World Journal of Gastroenterology;2024-06-07

4. Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib;ACG Case Reports Journal;2024-06

5. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24